Germline CDKN2A/p16 mutations are rare in multiple primary and familial malignant melanoma in German patients

Journal of Dermatological Science

Volumn 49, Issue 2, 2008, Pages 163-165

  Lukowsky, Ansgar ^a   Schäfer Hesterberg, Gregor ^a   Sterry, Wolfram ^a   Voit, Christiane ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CDKN2A p16; Germline mutations; Malignant melanoma

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

APOPTOSIS; CANCER PATIENT; CELL CYCLE ARREST; CHROMOSOME 9; EXON; FAMILIAL CANCER; GENE DELETION; GENE MUTATION; GERMANY; HUMAN; INTRON; LETTER; MELANOMA; MULTIPLE CANCER; PRIORITY JOURNAL;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; GERMANY; HUMANS; INTRONS; MELANOMA; NEOPLASMS, MULTIPLE PRIMARY; PEDIGREE; RISK FACTORS; SKIN NEOPLASMS;

EID: 37349115968     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2007.08.006     Document Type: Letter

References (10)

1. Goldstein A.M. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 23 (2004) 630-642
2. Monzon J., Liu L., Brill H., Goldstein A.M., Tucker M.A., From L., et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338 (1998) 879-887
3. Puig S., Malvehy J., Badenas C., Ruiz A., Jiminez D., Cuellar F., et al. Role of CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 23 (2005) 3043-3051
4. Berwick M., Orlow I., Hummer A.J., Armstrong B.K., Kricker A., Marrett L.D., et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 15 (2006) 1520-1525
5. Hussussian C.J., Struewing J.P., Goldstein A.M., Paul A.T., Higgins D.S.A., Sheahan M.D., et al. Germline p16 mutations in familial melanoma. Nat Genet 8 (1994) 15-21
6. Debniak T., Gorski B., Scott R.J., Cybulski C., Medrek K., Zlowocka E., et al. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer. Int J Cancer 110 (2004) 558-562
7. Marian C., Scope A., Laud K., Friedman E., Pavlotsky F., Yakobson E., et al. Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours. Br J Cancer 92 (2005) 2278-2285
8. Debniak T., Scott R.J., Huzarski T., Byrski T., Rozmiarek A., Debniak B., et al. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 65 (2005) 835-839
9. Bertram C.G., Gaut R.M., Barrett J.H., Pinney E., Whitaker L., Turner F., et al. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 119 (2002) 961-965
10. Spica T., Portela M., Gerard B., Formicone F., Descamps V., Crickx B., et al. The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations. J Invest Dermatol 126 (2006) 1657-1660